Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

September 16, 2024

Study Completion Date

September 16, 2028

Conditions

Oral Cavity Squamous Cell CarcinomaOral Squamous Cell CarcinomaOropharyngeal Squamous Cell Carcinoma

Interventions

DRUG

Sintilimab, Nab-paclitaxel, Carboplatin

Neoadjuvant Therapy

PROCEDURE

Surgical resection

Standard of care

DRUG

Sintilimab

Adjuvant Therapy

Trial Locations (1)

RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER